meRfi® logo
Medical Research Finder
House iconIcon chat dots
Icon question circle

meRfi®-GM

Clostridioides difficile infection (CDI) (recurrent) & Drugs/Treatments

Welcome to meRfi-GM!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Navigation

Contents

Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of Clostridioides difficile infection (CDI) pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the Clostridioides difficile infection (CDI)(brain://bQ4LAx9Ly0u1JoYHsdVoaQ/ClostridioidesDifficileInfectionCdi) drug discovery pipeline.
Monaghan et al. 2021 Expert Opinion on Therapeutic Targets 25(11): 949-963

Narrow-spectrum antibiotics have shown improved efficacy, but [fecal microbiota transplant (FMT) is highly effective in preventing rCDI](brain…